Hormone Therapy News

Among postmenopausal women, researchers observed no significant associations between ovarian steroids, adrenal hormones, insulin-like growth factor I, parathormone and vitamin D and handgrip strength, according to study results.

Social and economic determinants of health contribute to higher burden of HPV and HIV as well as lower likelihood of cancer screening among transgender and gender-diverse people, according to a review published in JAMA Oncology.

Transgender and nonbinary youths had greater appearance congruence — the experience that physical appearance aligns with gender —and less depression and anxiety after 2 years of gender-affirming hormone therapy, according to study data.

Women who use oral contraceptives are more likely to have an aldosterone-to-renin ratio above the threshold for a positive test for primary aldosteronism than those who do not use oral contraceptives, according to study data.

Postmenopausal women with hypertension taking estrogen alone or combined with progesterone had a statistically significant increase in systolic blood pressure compare with placebo, according to an analysis of WHI data.

Nearly three-quarters of people using testosterone therapy for gender affirmation reported pelvic pain, according to findings of an online survey published in LGBT Health.

Among postmenopausal women with vulvovaginal atrophy, ospemifene treatment and hormone therapy improved the vaginal microbiome in different ways, according to findings published in Menopause.

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

A pilot study published in Menopause highlighted racial disparities in the acceptance of systemic and local hormone therapy in perimenopausal and postmenopausal women.

An interim analysis of two phase 2 trials showed an oral medication was associated with beneficial height velocity outcomes among 50% of participants with pediatric growth hormone deficiency, according to a company press release.